These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 28898517

  • 1. Characterization of the functional activity of botulinum neurotoxin subtype B6.
    Kohda T, Nakamura K, Hosomi K, Torii Y, Kozaki S, Mukamoto M.
    Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
    [Abstract] [Full Text] [Related]

  • 2. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
    Kull S, Schulz KM, Weisemann J, Kirchner S, Schreiber T, Bollenbach A, Dabrowski PW, Nitsche A, Kalb SR, Dorner MB, Barr JR, Rummel A, Dorner BG.
    PLoS One; 2015 Nov; 10(2):e0116381. PubMed ID: 25658638
    [Abstract] [Full Text] [Related]

  • 3. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
    Davies JR, Rees J, Liu SM, Acharya KR.
    J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
    [Abstract] [Full Text] [Related]

  • 4. Identification and characterization of a novel botulinum neurotoxin.
    Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L, Miyashita SI, Martínez-Carranza M, Dong M, Stenmark P.
    Nat Commun; 2017 Aug 03; 8():14130. PubMed ID: 28770820
    [Abstract] [Full Text] [Related]

  • 5. Genetic characterization of Clostridium botulinum associated with type B infant botulism in Japan.
    Umeda K, Seto Y, Kohda T, Mukamoto M, Kozaki S.
    J Clin Microbiol; 2009 Sep 03; 47(9):2720-8. PubMed ID: 19571018
    [Abstract] [Full Text] [Related]

  • 6. Structural and Biochemical Characterization of Botulinum Neurotoxin Subtype B2 Binding to Its Receptors.
    Davies JR, Masuyer G, Stenmark P.
    Toxins (Basel); 2020 Sep 17; 12(9):. PubMed ID: 32957706
    [Abstract] [Full Text] [Related]

  • 7. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.
    Kroken AR, Blum FC, Zuverink M, Barbieri JT.
    Infect Immun; 2017 Jan 17; 85(1):. PubMed ID: 27795365
    [Abstract] [Full Text] [Related]

  • 8. Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay.
    James NG, Malik S, Sanstrum BJ, Rhéaume C, Broide RS, Jameson DM, Brideau-Andersen A, Jacky BS.
    Sci Rep; 2021 Apr 09; 11(1):7832. PubMed ID: 33837264
    [Abstract] [Full Text] [Related]

  • 9. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A).
    Kalb SR, Baudys J, Raphael BH, Dykes JK, Lúquez C, Maslanka SE, Barr JR.
    Anal Chem; 2015 Apr 07; 87(7):3911-7. PubMed ID: 25731972
    [Abstract] [Full Text] [Related]

  • 10. Genetic characterization and comparison of Clostridium botulinum isolates from botulism cases in Japan between 2006 and 2011.
    Kenri T, Sekizuka T, Yamamoto A, Iwaki M, Komiya T, Hatakeyama T, Nakajima H, Takahashi M, Kuroda M, Shibayama K.
    Appl Environ Microbiol; 2014 Nov 07; 80(22):6954-64. PubMed ID: 25192986
    [Abstract] [Full Text] [Related]

  • 11. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
    Zhou Y, Singh BR.
    Protein Expr Purif; 2004 Mar 07; 34(1):8-16. PubMed ID: 14766296
    [Abstract] [Full Text] [Related]

  • 12. Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain.
    Wang HH, Riding S, Lindo P, Singh BR.
    Appl Environ Microbiol; 2010 Oct 07; 76(19):6658-63. PubMed ID: 20693440
    [Abstract] [Full Text] [Related]

  • 13. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
    Lam KH, Sikorra S, Weisemann J, Maatsch H, Perry K, Rummel A, Binz T, Jin R.
    Pathog Dis; 2018 Jun 01; 76(4):. PubMed ID: 29688327
    [Abstract] [Full Text] [Related]

  • 14. Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.
    Matsumura T, Amatsu S, Misaki R, Yutani M, Du A, Kohda T, Fujiyama K, Ikuta K, Fujinaga Y.
    Toxins (Basel); 2020 May 07; 12(5):. PubMed ID: 32392791
    [Abstract] [Full Text] [Related]

  • 15. Botulinum neurotoxin X lacks potency in mice and in human neurons.
    Gregg BM, Matsumura T, Wentz TG, Tepp WH, Bradshaw M, Stenmark P, Johnson EA, Fujinaga Y, Pellett S.
    mBio; 2024 Mar 13; 15(3):e0310623. PubMed ID: 38347673
    [Abstract] [Full Text] [Related]

  • 16. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.
    Peng L, Berntsson RP, Tepp WH, Pitkin RM, Johnson EA, Stenmark P, Dong M.
    J Cell Sci; 2012 Jul 01; 125(Pt 13):3233-42. PubMed ID: 22454523
    [Abstract] [Full Text] [Related]

  • 17. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.
    Ambrin G, Kumar R, Singh BR.
    Toxicon; 2018 Mar 15; 144():34-41. PubMed ID: 29309744
    [Abstract] [Full Text] [Related]

  • 18. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
    Pellett S, Bradshaw M, Tepp WH, Pier CL, Whitemarsh RCM, Chen C, Barbieri JT, Johnson EA.
    mBio; 2018 Mar 27; 9(2):. PubMed ID: 29588398
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.